TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04330495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testing of SARS-CoV-2 and prescription of placebo (Hydroxychloroquine placebo) twice daily for 6 months
Study: NCT02266940
Drug: DS-1971a suspension
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
Study: NCT02266940
Drug: DS-1971a tablet
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 200 mg DS 1971a tablet for oral administration
Study: NCT01833169
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 100 mg (oral gelatine capsules) was administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28-day cycle
Study: NCT00105157
Drug: Comparator: MK0518
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0518 oral tablets 200 mg b.i.d, for 24 weeks
Study: NCT00105157
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to MK0518, oral tablet b.i.d, for 24 weeks
Study: NCT04011098
Drug: Epidural Fentanyl Bolus
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl bolus refers to the provision of a 2 ml bolus of epidural Fentanyl (50 mcg/ml; therefore a total dose of 100 mcg) after epidural placement, followed by a standard care infusion of epidural local anesthetic/opioids, with a PCEA pump for subsequent analgesia (0.08% Bupivicaine with 2 mcg/ml Fentanyl Solution).
Study: NCT04011098
Drug: Standard Epidural Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Control group will receive a 2 ml bolus of standard epidural mix solution (0.08% Bupivicaine with 2 mcg/ml Fentanyl) after epidural placement followed by standard care infusion of the same solution, with a PCEA pump for subsequent analgesia.
Study: NCT03037424
Drug: Cryoprecipitate
Normalized name: Cryoprecipitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
Study: NCT02889302
Drug: KPS-0373
Normalized name: Draxxin KP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks
Study: NCT02889302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks
Study: NCT02966340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00658593
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01550380
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
Study: NCT02977689
Drug: IDH305
Approvals — FDA: no, EMA: no, PMDA: no
Description: study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
Study: NCT00707707
Drug: AZD2281
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose finding study to establish the appropriate dose of AZD2281
Study: NCT01104948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259348
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV)
Study: NCT00929981
Drug: Tablet Methylprednisolone (4 or 16 mg)
Normalized name: methylprednisolone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
Study: NCT02520453
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01585428
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
Study: NCT00131482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
Study: NCT00806962
Drug: Adjuvant/Excipients
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
Study: NCT02502968
Drug: Placebo (for BL-8040)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for solution for injection manufactured to mimic BL-8040
Study: NCT01056926
Drug: Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
Study: NCT03535103
Drug: Gonal-F®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single Subcutaneous injection, 225IU
Study: NCT00815945
Drug: PegLiposomal Doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
Study: NCT00608231
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
Study: NCT02564042
Drug: GSK2894512 1% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Study: NCT02564042
Drug: GSK2894512 0.5% Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Study: NCT02564042
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off-white vehicle cream base to be applied topically
Study: NCT00396955
Drug: PLA-695
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00006034
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04556734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrasimod matching placebo tablet by mouth, once daily
Study: NCT01349790
Drug: NewGam
Approvals — FDA: no, EMA: no, PMDA: no
Description: NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
Study: NCT04058145
Drug: AMD3100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.
Study: NCT02937506
Drug: Fentanyl Plus Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
Study: NCT03589443
Drug: Multiplexed heptapeptides
Normalized name: hexapeptide-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptapeptides QRH and KSP
Study: NCT03686163
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks
Study: NCT01142700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Oral, 0 mg, once daily
Study: NCT01069796
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 \& 3
Study: NCT00779467
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl 2 mcg/ml
Study: NCT00617123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo oral tablet
Study: NCT02289898
Drug: Abraxane®
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously
Study: NCT02289898
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04622124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02846883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of Plasmalyte A (placebo)
Study: NCT00676650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37.5 mg/day, oral, administered on a continuous daily dosing regimen
Study: NCT04262739
Drug: NYH817G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject will orally administer NYH817G (15 mg) during the cycles(21 days)
Study: NCT01659151
Drug: Lymphodepletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion.
Study: NCT02697617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01257581
Drug: creatine
Normalized name: Creatine
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: creatine monohydrate powder
Study: NCT00381849
Drug: Cystone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 2 pills, 2 times a day.~Each tablet of Cystone contains:~Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg.
Study: NCT05544656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo administered three times a day
Study: NCT02937207
Drug: Ke Chuan Liu Wei Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experience formula of famous traditional Chinese professor Yingen Wu
Study: NCT02937207
Drug: Chuan Xiong Ping Chuan Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experience formula of famous traditional Chinese professor Changrong Shao
Study: NCT02937207
Drug: Zhi Chuan Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experience formula of famous traditional Chinese professor Yingen Wu
Study: NCT02937207
Drug: Ke Chuan Liu Wei Mixture placebo
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
Study: NCT02937207
Drug: Chuan Xiong Ping Chuan Mixture placebo
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
Study: NCT02937207
Drug: Xie Wu Capsule placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose combination for treating prescription of Xie Wu Capsule
Study: NCT02937207
Drug: Dan Ma Jia Tablet placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose combination for treating prescription of Dan Ma Jia Tablet
Study: NCT01765270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg placebo tablet daily
Study: NCT01628549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched Placebo capsule administered as an oral capsule(s) once daily
Study: NCT01628549
Drug: 100 mg P005672-HCl
Normalized name: tetracycline hydrochloride 100 MG
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P005672-HCl administered as an oral capsule(s) once daily
Study: NCT03368391
Drug: 2% Lidocaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of 2% Lidocaine with 1:100,000 epi will be infiltrated at anterior teeth
Study: NCT03368391
Drug: 3% Mepivacaine with 1:100,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mL of 3% Mepivacaine will be infiltrated at anterior teeth
Study: NCT03368391
Drug: saline intranasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mL intranasal saline will be administered as a placebo
Study: NCT03368391
Drug: saline infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 mL of saline will be infiltrated at anterior teeth as a placebo
Study: NCT02351167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00547625
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
Study: NCT03078257
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.
Study: NCT00446784
Drug: CE-224,535
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01085578
Drug: CG400549/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
Study: NCT01085578
Drug: CG400549/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
Study: NCT01085578
Drug: CG400549
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
Study: NCT04478526
Drug: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Approvals — FDA: no, EMA: no, PMDA: no
Description: If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will begin either. If deemed unresponsive to either prior to study, commence medication they have not been previously unresponsive to. Unresponsive if GAD did not improve after treatment with maximum tolerated dose for 8-weeks. If deemed unresponsive to SSRI and SNRI/pregabalin, commence secondary medication arm (bupropion/mirtazepine, buspirone/imipramine) with both being described to patient and begin either. Switch protocol: If unresponsive after 4 or 6 weeks, switch to another class. If started in primary or secondary and not previously demonstrated non-response to second class of medications within arm, switch to second class within arm. If started in primary and previously deemed unresponsive to second class, begin secondary if non-response indicates switch necessary.
Study: NCT00446784
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02828566
Drug: IN saline 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 0.9% normal saline
Study: NCT02828566
Drug: IV saline 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% normal saline
Study: NCT01737541
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04398134
Drug: ABI-H2158
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 X 100 mg tablets for oral administration
Study: NCT04398134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic the ABI-H2158 tablets
Study: NCT02992548
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01529554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
Study: NCT04009876
Drug: nal-IRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with 5-FU/LV + Oxaliplatin + nal-IRI for 8 cycles followed by standard chemoradiation (5 weeks)
Study: NCT03419962
Drug: MaxSpiolto® Respimat® 160 Characters...
Approvals — FDA: no, EMA: no, PMDA: no
Description: as per the approved SmPC
Study: NCT00915187
Drug: CCS/C
Normalized name: Calcium Carbonate/Calcium Sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant to influenza vaccine
Study: NCT00248092
Drug: NRP104
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01386125
Drug: Placebo for MFNS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sprays in each nostril BID for up to 16 weeks
Study: NCT01781234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00721955
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled loxapine Placebo, may repeat after 2 hours x 2
Study: NCT01928615
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy for early breast cancer.
Study: NCT00515216
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00136656
Drug: antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
Study: NCT02459886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03281096
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pill manufactured to mmic Berberine hydrochloride 100mg tablet
Study: NCT01828437
Drug: Pyridoxine plus prednisolone
Normalized name: prednisolone acetate Ophthalmic Suspension [Econopred Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01828437
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00344045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
Study: NCT00875082
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
Study: NCT00006124
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02798419
Drug: DFD05 Cream
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004196
Drug: Observation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02767947
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream will be applied per schedule specified in the arm.
Study: NCT02994290
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
Study: NCT04253236
Drug: RVT-1401 680 mg/weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
Study: NCT02846233
Drug: GLP1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide or Dulaglutide will be added to a basal insulin.
Study: NCT01896505
Drug: KCP-330
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02185963
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20mg once a daily for 12 weeks
Study: NCT01327521
Drug: CT Contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT01327521
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care
Study: NCT00559741
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00559741
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03743259
Drug: LuminoMark inj. 0.1mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.
Study: NCT03743259
Drug: LuminoMark inj. 0.2mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.
Study: NCT03743259
Drug: Charcotrace Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection Charcotrace Inj. about 0.3\~1mL once in this study.
Study: NCT04606017
Drug: Caltrate Pill
Normalized name: Caltrate Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
Study: NCT00597428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mcg capsules twice daily (BID)
Study: NCT00170144
Drug: Branchamin 4%
Normalized name: BranchAmin 4% Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03785691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet (empty gelatine capsule) will be administered twice daily (morning and bedtime) for 7 days.~On Day 7 dosage increase is optional. If desired, placebo oral tablet (empty gelatine capsule) will be administered four times daily (morning, noon, late afternoon and bedtime) for 7 days. In case dosage increase is not desired, the subject will continue the initial treatment for an additional 7 days.
Study: NCT02269735
Drug: MK-2640
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-2640 intravenous infusion administered to participant in a fasted state
Study: NCT02269735
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
Study: NCT00230191
Drug: RK-0202
Approvals — FDA: no, EMA: no, PMDA: no